Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Sun Pharmaceutical Industries Ltd. Share Price
Day's Range
Day's Range
Low
₹1,847.40
High
₹1,858.80
Price Summary
| Previous Close | ₹1,856.40 |
|---|---|
| Day's Range | ₹1,847.40 - ₹1,858.80 |
| Open | ₹1,853.50 |
| 52 Week Range | ₹1,548.00 - ₹2,046.90 |
| Volume | 84,307 |
| Market Cap | ₹0.44 |
| Previous Close | ₹1,858.50 |
|---|---|
| Day's Range | ₹1,846.80 - ₹1,858.50 |
| Open | ₹1,857.75 |
| 52 Week Range | ₹1,547.25 - ₹2,047.55 |
| Volume | 3,833 |
| Market Cap | ₹0.44 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1,565.08 |
|---|---|
| Market Cap (₹ in Mn) | 0.44 |
| Dividend Yield(%) | 0.86 |
| Price/Earning (TTM) | 36.77 |
| TTM EPS (₹) | 50.41 |
| P/E Ratio | 36.73 |
| Book Value(₹) | 5.14 |
| PAT Margin (%) | 19.78 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 19.11 |
| Trade Value ( ₹ in Lacs) | 71.24 |
|---|---|
| Market Cap (₹ in Mn) | 0.44 |
| Dividend Yield(%) | 0.86 |
| Price/Earning (TTM) | 36.77 |
| TTM EPS (₹) | 50.41 |
| P/E Ratio | 36.73 |
| Book Value(₹) | 5.14 |
| PAT Margin (%) | 19.78 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 19.11 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 138514.0 | 525784.4 |
| Expenses | N/A | N/A |
| PBT | 31630.2 | 137367.8 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 22928.7 | 109647.5 |
About Sun Pharmaceutical Industries Ltd.
| Founded | 1993 |
|---|---|
| Managing Director | Kirti Ganorkar |
| NSE Symbol | SUNPHARMA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,44,716.74 | 1,858.50 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,44,223.13 | 9,280.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,83,453.32 | 4,811.70 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,25,278.85 | 8,775.00 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,17,820.60 | 679.70 | 0.00 - 0.00 |
| Zydus Lifesciences Ltd. | 1,10,224.17 | 1,109.10 | 835.50 - 835.50 |
| Cipla Ltd. | 1,09,848.55 | 1,357.80 | 1,165.70 - 1,165.70 |
| Laurus Labs Ltd. | 1,02,983.51 | 1,930.95 | 823.10 - 823.10 |
| Max Healthcare Institute Ltd. | 1,00,504.02 | 1,032.05 | 903.00 - 903.00 |
| Dr. Reddy's Laboratories Ltd. | 95,591.76 | 1,149.90 | 1,101.00 - 1,101.00 |
No Records Found
Latest News
Sun Pharmaceutical Industries informs about incorporation of subsidiary company
Sun Pharmaceutical Industries has informed that ‘Sun Pharma Global Treasury Centre IFSC’ has been incorporated on 08 September 2026 as an indirect wholly owned subsidiary of the Company in the International Financial Services Centre at GIFT City, Gandhinagar, Gujarat, India. The disclosures required under Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure A.
The above information is a part of company’s filings submitted to BSE.
Sun Pharmaceutical Industries informs about press release
Sun Pharmaceutical Industries informs about update
Sun Pharmaceutical Industries has informed that the company and certain of its subsidiaries have been defendants in antitrust litigation in the United States relating to a 2008 patent litigation settlement agreement with Pfizer concerning generic Lipitor (Atorvastatin). Plaintiffs alleged that the settlement unlawfully delayed generic competition for Lipitor and that absent the unlawful settlement, Lipitor would have entered the market earlier than it did. The matter has been disclosed from time to time in the Company's financial statements. The United States Court of Appeals for the Third Circuit has affirmed the order of the United States District Court granting summary judgment in its entirety in favour of the Company and its subsidiaries. The Appellate Court has also affirmed the District Court's orders denying class certification as to the plaintiffs. This decision represents a significant favourable development for the Company and its subsidiaries in the matter, and brings the litigation substantially to a close, subject to any further remedies that may be available to the plaintiffs under applicable law.
The above information is a part of company’s filings submitted to BSE.
Sun Pharmaceutical Industries informs about press release
Sun Pharmaceutical Industries informs about press release
Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release titled ‘Sun Pharma receives approval to manufacture and market generic semaglutide in South Africa,’ which shall be released after this intimation.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Sun Pharmaceutical Industries Ltd. is ₹1,857.50 as of 2026-09-17.
The market capitalisation of Sun Pharmaceutical Industries Ltd. is ₹444,716.74 as of 2026-09-16.
The 1-year return of Sun Pharmaceutical Industries Ltd. is 247.00% as of 2026-09-17.
The P/E ratio of Sun Pharmaceutical Industries Ltd. is 36.73 as of 2026-09-17.
The 52-week high and low of Sun Pharmaceutical Industries Ltd. are ₹2,046.90 and ₹1,548.00, respectively, as of 2026-09-17.
People Also Ask
Sun Pharmaceutical Industries Ltd. offers more than 2,000 molecules across generics, branded generics, specialty medicines, OTC and APIs, covering key therapy areas such as cardiology, psychiatry, neurology, dermatology, oncology, ophthalmology and diabetes care in over 100 countries.
Sun Pharmaceutical Industries Ltd. expands access to medicines through licensing agreements for key molecules in areas like HIV, COVID-19 and dermatology, working with partners such as Merck, Philogen, Aclaris and China Medical System to reach hospital and public-sector patients.
Sun Pharmaceutical Industries Ltd and Organon have engaged in certain commercial and product-related collaborations; however, Organon has not been publicly announced as an acquisition by Sun Pharma.
Sun Pharmaceutical Industries Ltd is a publicly listed pharmaceutical company traded on both NSE and BSE in India.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
